Chiltern grows market share in FY 2010; plans global expansion

By Gareth Macdonald

- Last updated on GMT

Related tags Contract research organization Chiltern

CRO Chiltern International says market share grew in fiscal 2010, citing strengthened industrial relationships and global expansion as drivers.

For the 12-months ended March 31, the privately-owned contract research organisation (CRO) posted revenue of £81m (€97m), an increase of some 10 per cent on the amount earned in the previous financial year.

CEO Glenn Kerkhof said the year had seen considerable growth of new business awards, up 16 per cent to £134m, which “increased [Chiltern’s] market share.”

Kerkhof also ​partly attributed Chiltern’s improved performance over the period to “[the] relationships we are building with our pharmaceutical and biotechnology clients​.”

He did not disclose which specific customers had been most important to Chiltern's business, other than to say that the firm's largest drug industry client had contributed 7.8 per cent of its revenue.

Global network

Kerkhof also hinted at Chiltern’s plans for the next 12-months, explaining that: “We continue to develop the Chiltern brand and expand our geographic network and are looking forward to another year of growth and development​.”

Again, while further information on the expansion was not forthcoming, the comments suggest the UK CRO’s recently​ opened offices in Australia and Singapore may not be the last it sets up over the next 12-months.

Further support for this idea comes from the fact that global growth has also been very much on the agenda at Chiltern’s owner Czura Thornton in recent times.

Speaking after​ the US investment group acquired Clearstone from MDS last year​, former Chiltern executive and Czua Thorton co-founder Nick Thornton said the contract services firms would work together to expand into new geographies.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more